WO2004110350A3 - Compouds and uses thereof in modulating amyloid beta - Google Patents

Compouds and uses thereof in modulating amyloid beta Download PDF

Info

Publication number
WO2004110350A3
WO2004110350A3 PCT/US2004/015239 US2004015239W WO2004110350A3 WO 2004110350 A3 WO2004110350 A3 WO 2004110350A3 US 2004015239 W US2004015239 W US 2004015239W WO 2004110350 A3 WO2004110350 A3 WO 2004110350A3
Authority
WO
WIPO (PCT)
Prior art keywords
compouds
amyloid beta
modulating amyloid
modulating
levels
Prior art date
Application number
PCT/US2004/015239
Other languages
French (fr)
Other versions
WO2004110350A2 (en
Inventor
Soan Cheng
Daniel D Comer
Long Mao
Guity P Balow
David Pleynet
Original Assignee
Neurogenetics Inc
Soan Cheng
Daniel D Comer
Long Mao
Guity P Balow
David Pleynet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogenetics Inc, Soan Cheng, Daniel D Comer, Long Mao, Guity P Balow, David Pleynet filed Critical Neurogenetics Inc
Priority to BRPI0410348-3A priority Critical patent/BRPI0410348A/en
Priority to JP2006533094A priority patent/JP4847868B2/en
Priority to EP04752297.4A priority patent/EP1628666B1/en
Priority to MXPA05012281A priority patent/MXPA05012281A/en
Priority to AU2004247013A priority patent/AU2004247013B2/en
Priority to CA2525547A priority patent/CA2525547C/en
Publication of WO2004110350A2 publication Critical patent/WO2004110350A2/en
Publication of WO2004110350A3 publication Critical patent/WO2004110350A3/en
Priority to IL171471A priority patent/IL171471A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Novel compounds, compositions, and kits are provided. Methods of modulating Aβ levels, and methods of treating a disease associated with aberrant Aβ levels are also provided.
PCT/US2004/015239 2003-05-14 2004-05-14 Compouds and uses thereof in modulating amyloid beta WO2004110350A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
BRPI0410348-3A BRPI0410348A (en) 2003-05-14 2004-05-14 compounds and uses thereof in amyloid-beta modulation
JP2006533094A JP4847868B2 (en) 2003-05-14 2004-05-14 Compounds and their use in the regulation of amyloid beta
EP04752297.4A EP1628666B1 (en) 2003-05-14 2004-05-14 Compouds and uses thereof in modulating amyloid beta
MXPA05012281A MXPA05012281A (en) 2003-05-14 2004-05-14 Compouds and uses thereof in modulating amyloid beta.
AU2004247013A AU2004247013B2 (en) 2003-05-14 2004-05-14 Compounds and uses thereof in modulating amyloid beta
CA2525547A CA2525547C (en) 2003-05-14 2004-05-14 Compounds and uses thereof in modulating amyloid beta
IL171471A IL171471A (en) 2003-05-14 2005-10-19 Compounds useful in modulating amyloid beta, compositions and kits comprising them and their use in preparation of medicaments

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47088403P 2003-05-14 2003-05-14
US60/470,884 2003-05-14
US53226003P 2003-12-22 2003-12-22
US60/532,260 2003-12-22

Publications (2)

Publication Number Publication Date
WO2004110350A2 WO2004110350A2 (en) 2004-12-23
WO2004110350A3 true WO2004110350A3 (en) 2005-03-03

Family

ID=33555297

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/015239 WO2004110350A2 (en) 2003-05-14 2004-05-14 Compouds and uses thereof in modulating amyloid beta

Country Status (11)

Country Link
US (5) US7244739B2 (en)
EP (1) EP1628666B1 (en)
JP (2) JP4847868B2 (en)
KR (1) KR20060023529A (en)
CN (1) CN102584813B (en)
AU (1) AU2004247013B2 (en)
BR (1) BRPI0410348A (en)
CA (1) CA2525547C (en)
IL (1) IL171471A (en)
MX (1) MXPA05012281A (en)
WO (1) WO2004110350A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9365548B2 (en) 2006-03-31 2016-06-14 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
US9434715B2 (en) 2013-03-06 2016-09-06 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine modulators of the histamine H4 receptor

Families Citing this family (212)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002064084A2 (en) * 2000-11-02 2002-08-22 Cornell Research Foundation, Inc. In vivo multiphoton diagnostic detection and imaging of a neurodegenerative disease
BRPI0410348A (en) * 2003-05-14 2006-05-30 Torreypines Therapeutics Inc compounds and uses thereof in amyloid-beta modulation
EP1689722A2 (en) 2003-10-10 2006-08-16 Bayer Pharmaceuticals Corporation 4-aminopyrimidine derivatives for treatment of hyperproliferative disorders
JP4928949B2 (en) 2003-12-23 2012-05-09 アステックス、セラピューティックス、リミテッド Pyrazole derivatives as protein kinase modulators
NZ551144A (en) 2004-05-26 2009-12-24 Eisai R&D Man Co Ltd Cinnamide compound
DE602005024274D1 (en) 2004-07-16 2010-12-02 Sunesis Pharmaceuticals Inc AS AURORA KINASE INHIBITORS USEFUL THIENOPYRIMIDINE
US7777036B2 (en) 2004-09-20 2010-08-17 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
AR051093A1 (en) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc HETEROCICLIC DERIVATIVES AND THEIR USE AS INHIBITORS OF ESTEAROIL-COA DESATURASA
BRPI0515489A (en) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc heterocyclic derivatives and their use as stearoyl coat desaturase inhibitors
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
JP5094398B2 (en) 2004-09-20 2012-12-12 ゼノン・ファーマシューティカルズ・インコーポレイテッド Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturases
EP2266569A3 (en) 2004-09-20 2011-03-09 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
US7919496B2 (en) 2004-09-20 2011-04-05 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
US7449486B2 (en) 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
DE602005019602D1 (en) 2004-10-26 2010-04-08 Eisai R&D Man Co Ltd AMORPHIC FORM OF A CINEMA ACID AMID CONNECTION
UA95907C2 (en) * 2005-05-02 2011-09-26 Эррей Биофарма Инк. Mitotic kinesin inhibitors and methods of use thereof
UA92746C2 (en) 2005-05-09 2010-12-10 Акилайон Фармасьютикалз, Инк. Thiazole compounds and methods of use
KR20080014024A (en) * 2005-05-11 2008-02-13 아보트 러보러터리즈 Antagonists of the vanilloid receptor subtype 1(vr1) and uses thereof
AU2006343359A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
EP1902032A1 (en) 2005-06-22 2008-03-26 Astex Therapeutics Limited Pharmaceutical compounds
WO2006136837A2 (en) 2005-06-23 2006-12-28 Astex Therapeutics Limited Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
NZ566036A (en) * 2005-09-13 2010-06-25 Janssen Pharmaceutica Nv 2-Aniline-4-aryl substituted thiazole derivatives that modulate the alpha7 nicotinic receptor
CN101309916A (en) * 2005-11-18 2008-11-19 卫材R&D管理有限公司 Process for production of cinnamamide derivative
WO2007058304A1 (en) * 2005-11-18 2007-05-24 Eisai R & D Management Co., Ltd. Salts of cynnamide compound or solvates thereof
TWI370130B (en) * 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
BRPI0618814A2 (en) 2005-11-24 2014-04-29 Eisai R&D Man Co Ltd COMPOUND OR PHARMACOLOGICALLY ACCEPTABLE SALT OF THE SAME, AND PHARMACEUTICAL AGENT
JP4738419B2 (en) 2005-11-30 2011-08-03 富士フイルムＲｉファーマ株式会社 Diagnostic and therapeutic agents for diseases caused by amyloid aggregation and / or deposition
UA96936C2 (en) 2005-12-29 2011-12-26 Лексикон Фармасьютикалз, Инк. Multicyclic amino acid derivatives and methods of their use
TWI378091B (en) * 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
TWI417095B (en) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mglur2-receptors
UA97474C2 (en) 2006-03-31 2012-02-27 Новартис Аг Compounds for treating disorders associated with dgat1 activity
EP2019094A4 (en) * 2006-05-19 2011-01-05 Eisai R&D Man Co Ltd Heterocyclic type cinnamide derivative
WO2007135969A1 (en) * 2006-05-19 2007-11-29 Eisai R & D Management Co., Ltd. Urea type cinnamide derivative
MX2008015226A (en) 2006-05-30 2008-12-12 Astrazeneca Ab 1, 3, 4 -oxadiazole derivatives as dgat1 inhibitors.
TW200811134A (en) 2006-07-12 2008-03-01 Irm Llc Compounds and compositions as protein kinase inhibitors
AR062095A1 (en) * 2006-07-28 2008-10-15 Eisai R&D Man Co Ltd CINAMIDE COMPOUND PROFARMACO
WO2008042928A2 (en) * 2006-10-03 2008-04-10 Array Biopharma, Inc. Oxadiazole and thiadiazole derivatives as mitotic kinesin inhibitors and methods of use thereof
JP5160764B2 (en) * 2006-10-13 2013-03-13 全薬工業株式会社 Antidepressant, brain protectant, amyloid β deposition inhibitor or aging inhibitor containing a heterocyclic compound having a specific structure
US8106070B2 (en) 2006-10-20 2012-01-31 Merck Sharp & Dohme Corp. Substituted imidazoles as bombesin receptor subtype-3 modulators
AU2007309570B2 (en) 2006-10-20 2012-07-12 Merck Sharp & Dohme Corp. Substituted imidazoles as bombesin receptor subtype-3 modulators
CA2667003A1 (en) 2006-10-20 2008-05-02 Merck & Co., Inc. Substituted imidazoles as bombesin receptor subtype-3 modulators
SG173409A1 (en) * 2006-11-24 2011-08-29 Ac Immune Sa N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers
UA99270C2 (en) * 2006-12-12 2012-08-10 Лексикон Фармасьютикалз, Инк. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
US20100204230A1 (en) 2007-02-12 2010-08-12 Peter Blurton Piperazine derivatives for treatment of ad and related conditions
EP2120573A4 (en) * 2007-02-12 2011-05-25 Merck Sharp & Dohme Piperidine derivatives
TW200848054A (en) * 2007-02-28 2008-12-16 Eisai R&D Man Co Ltd Two cyclic oxomorpholine derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
WO2008137102A2 (en) * 2007-05-04 2008-11-13 Torreypines Therapeutics, Inc. Methods of modulating amyloid beta and compounds useful therefor
MX2009012177A (en) 2007-05-07 2009-11-23 Schering Corp Gamma secretase modulators.
AU2008250436B2 (en) 2007-05-11 2013-03-28 F. Hoffmann-La Roche Ag Hetarylanilines as modulators for amyloid beta
WO2008140111A1 (en) * 2007-05-16 2008-11-20 Eisai R & D Management Co., Ltd. One-pot production process for cinnamide derivative
CN101801964A (en) * 2007-05-22 2010-08-11 艾其林医药公司 Heteroaryl substituted thiazoles and their use as antiviral agents
AU2008263207B2 (en) 2007-06-01 2013-10-03 Merck Sharp & Dohme Corp. Gamma secretase modulators
EP2164852A2 (en) 2007-06-01 2010-03-24 Schering Corporation Gamma secretase modulators
EP2166854A4 (en) * 2007-06-13 2012-05-16 Merck Sharp & Dohme Triazole derivatives for treating alzheimer's disease and related conditions
CN101743242A (en) * 2007-06-29 2010-06-16 苏尼西斯制药有限公司 Heterocyclic compounds useful as RAF kinase inhibitors
AR067354A1 (en) 2007-06-29 2009-10-07 Sunesis Pharmaceuticals Inc USEFUL COMPOUNDS AS INHIBITORS OF RAF QUINASA
WO2009020580A1 (en) * 2007-08-06 2009-02-12 Schering Corporation Gamma secretase modulators
JP5599312B2 (en) 2007-08-22 2014-10-01 アイアールエム・リミテッド・ライアビリティ・カンパニー 5- (4- (haloalkoxy) phenyl) pyrimidin-2-amine compounds and compositions as kinase inhibitors
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
JP5433418B2 (en) 2007-08-31 2014-03-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 Polycyclic compound
JP2009079037A (en) * 2007-09-06 2009-04-16 Sumitomo Chemical Co Ltd PHARMACEUTICAL COMPOSITION FOR INHIBITING AMYLOID beta-PROTEIN ACCUMULATION
JP2010538068A (en) 2007-09-06 2010-12-09 シェーリング コーポレイション Gamma secretase modulator
KR20100080597A (en) 2007-09-14 2010-07-09 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 1,3-disubstituted-4-phenyl-1h-pyridin-2-ones
EP2203439B1 (en) 2007-09-14 2011-01-26 Ortho-McNeil-Janssen Pharmaceuticals, Inc. 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-ý1, 4'¨bipyridinyl-2'-ones
WO2009033702A1 (en) 2007-09-14 2009-03-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
JO2784B1 (en) 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 1,3,5-trisubstitued triazole derivative
MX2010004177A (en) 2007-10-18 2010-05-03 Janssen Pharmaceutica Nv Trisubstituted 1,2,4-triazoles.
US8168800B2 (en) * 2007-11-02 2012-05-01 The Regents Of The University Of California Aβ-binding small molecules
MX2010005028A (en) 2007-11-05 2010-05-27 Schering Corp Gamma secretase modulators.
EP2220083B1 (en) 2007-11-14 2017-07-19 Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
WO2009067493A2 (en) * 2007-11-19 2009-05-28 Envivo Pharmaceuticals, Inc. 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders
US20100298359A1 (en) * 2007-12-06 2010-11-25 Xianhai Huang Gamma secretase modulators
KR20100094554A (en) * 2007-12-06 2010-08-26 쉐링 코포레이션 Gamma secretase modulators
WO2009076352A1 (en) 2007-12-11 2009-06-18 Schering Corporation Gamma secretase modulators
WO2009075874A1 (en) * 2007-12-13 2009-06-18 Amgen Inc. Gamma secretase modulators
AU2008345573B2 (en) 2007-12-20 2013-12-19 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
JP5662803B2 (en) 2007-12-20 2015-02-04 アストラゼネカ アクチボラグ Carbamoyl compounds 190 as DGAT1 inhibitors
WO2009080533A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Heteroaryl derivatives as orexin receptor antagonists
JP5306373B2 (en) * 2008-01-11 2013-10-02 エフ．ホフマン−ラ ロシュ アーゲー Amyloid β modulator
CN101925607A (en) * 2008-01-28 2010-12-22 卫材R&D管理有限公司 Crystalline cinnamide compounds or salts thereof
CA2713716A1 (en) 2008-02-22 2009-08-27 F. Hoffmann-La Roche Ag Modulators for amyloid beta
US20110105436A1 (en) * 2008-03-10 2011-05-05 Auckland Uniservices Limited Heteroaryl compounds, compositions, and methods of use in cancer treatment
EA018186B1 (en) 2008-03-19 2013-06-28 Янссен Фармацевтика Нв Trisubstituted 1,2,4-triazoles as nicotinic acetylcholine receptor modulators
AU2009245715B2 (en) 2008-05-09 2014-01-09 Janssen Pharmaceutica Nv Trisubstituted pyrazoles as acetylcholine receptor modulators
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
CA2724413C (en) * 2008-05-15 2016-10-18 Duke University Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof
JP5400878B2 (en) * 2008-06-24 2014-01-29 アイアールエム・リミテッド・ライアビリティ・カンパニー Compounds and methods for modulating G protein coupled receptors
US8124764B2 (en) 2008-07-14 2012-02-28 Gilead Sciences, Inc. Fused heterocyclyc inhibitor compounds
EP2303841A1 (en) 2008-07-14 2011-04-06 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
CA2729909A1 (en) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Imidazolyl pyrimidine inhibitor compounds
KR20110038159A (en) 2008-07-28 2011-04-13 길리애드 사이언시즈, 인코포레이티드 Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds
CA2735764C (en) 2008-09-02 2016-06-14 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
MX349711B (en) * 2008-09-18 2017-08-09 Cedars Sinai Medical Center Optical method for the detection of alzheimer's disease.
CN102177151A (en) 2008-10-09 2011-09-07 弗·哈夫曼-拉罗切有限公司 Modulators for amyloid beta
CN102186477B (en) 2008-10-16 2013-07-17 奥梅-杨森制药有限公司 Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
WO2010053438A1 (en) 2008-11-06 2010-05-14 Astrazeneca Ab Modulators of amyloid beta.
JP5378532B2 (en) * 2008-11-10 2013-12-25 エフ．ホフマン−ラ ロシュ アーゲー Heterocyclic γ-secretase modulator
EP2365976B1 (en) 2008-11-13 2015-04-15 Merck Sharp & Dohme Corp. Gamma secretase modulators
JP2012508748A (en) 2008-11-13 2012-04-12 シェーリング コーポレイション γ-secretase modulator
BRPI0921333A2 (en) 2008-11-28 2015-12-29 Addex Pharmaceuticals Sa indole and benzoxazine derivatives as metabotropic glutamate receptor modulators
US20110313001A1 (en) * 2008-12-16 2011-12-22 Christian Fischer Triazole derivatives for treatment of alzheimer's disease
US8575150B2 (en) 2008-12-16 2013-11-05 Merck Sharp & Dohme Corp. Triazole derivatives for treatment of Alzheimer's disease
PA8854101A1 (en) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm IMIDAZOL BICYCLIC DERIVATIVES REPLACED AS MODULATORS OF GAMMA SECRETASA
AU2009330233A1 (en) 2008-12-22 2011-07-07 Merck Sharp & Dohme Corp. Gamma secretase modulators
TW201035103A (en) 2008-12-22 2010-10-01 Schering Corp Gamma secretase modulators
GB0900388D0 (en) 2009-01-12 2009-02-11 Addex Pharmaceuticals Sa New compounds
WO2010089292A1 (en) 2009-02-06 2010-08-12 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators
TWI461425B (en) * 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc Novel substituted benzoxazole, benzimidazole, oxazolopyridine and imidazopyridine derivatives as gamma secretase modulators
JP2012051807A (en) * 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd Arylimidazole compound
EP2401276B1 (en) 2009-02-26 2013-06-05 Eisai R&D Management Co., Ltd. Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
JP2012051806A (en) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd Imidazolylpyrazine derivative
BRPI1007883A2 (en) 2009-02-26 2016-02-23 Eisai R&D Man Co Ltd salt and crystal.
MX2011011753A (en) * 2009-05-07 2011-11-29 Janssen Pharmaceuticals Inc Novel substituted indazole and aza-indazole derivatives as gamma secretase modulators.
US9023767B2 (en) * 2009-05-07 2015-05-05 Memorial Sloan-Kettering Cancer Center γ-Secretase substrates and methods of use
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
PL2430022T3 (en) 2009-05-12 2014-02-28 Janssen Pharmaceuticals Inc 1,2,4-Triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
MY153912A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 1, 2, 4,-triazolo[4,3-a[pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MX2011013165A (en) 2009-06-08 2012-01-30 Gilead Sciences Inc Alkanoylamino benzamide aniline hdac inihibitor compounds.
AU2010259042A1 (en) 2009-06-08 2011-12-15 Gilead Sciences, Inc. Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds
WO2010147973A1 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
WO2010147975A1 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
US20120238546A1 (en) 2009-06-16 2012-09-20 Zhaoning Zhu Gamma secretase modulators
UY32716A (en) 2009-06-19 2011-01-31 Astrazeneca Ab PIRAZINE CARBOXAMIDE COMPOUNDS USEFUL FOR THE TREATMENT OF DIABETES AND OBESITY
JP2012180281A (en) * 2009-06-29 2012-09-20 Dainippon Sumitomo Pharma Co Ltd New oxadiazole derivative
CA2767764A1 (en) 2009-07-13 2011-01-20 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
ES2519565T3 (en) * 2009-07-15 2014-11-07 Janssen Pharmaceuticals Inc. Triazole and imidazole derivatives substituted as gamma secretase modulators
CA2772797C (en) 2009-09-30 2018-09-25 Transtech Pharma, Inc. Substituted imidazole derivatives
EP2311823A1 (en) 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
US8871460B2 (en) 2009-11-09 2014-10-28 Neurogenetic Pharmaceuticals, Inc. Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
KR20120123677A (en) 2010-01-15 2012-11-09 얀센 파마슈티칼즈, 인코포레이티드 Novel substituted bicyclic triazole derivatives as gamma secretase modulators
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
ES2550667T3 (en) 2010-02-18 2015-11-11 Vtv Therapeutics Llc Phenylheteroaryl derivatives and methods of use thereof
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
ES2482146T3 (en) 2010-04-30 2014-08-01 Ivoclar Vivadent Ag Dental oven
US9403815B2 (en) 2010-06-24 2016-08-02 The Regents Of The University Of California Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms
CA2809779A1 (en) 2010-09-02 2012-03-08 Takeda Pharmaceutical Company Limited Fused triazoles for the treatment or prophylaxis of mild cognitive impairment
WO2012033831A2 (en) 2010-09-07 2012-03-15 Memorial Sloan-Kettering Cancer Center Methods and compositions for gamma-secretase assay
PT2649069E (en) 2010-11-08 2015-11-20 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
AU2011328195B2 (en) 2010-11-08 2015-04-02 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
CN103298809B (en) 2010-11-08 2016-08-31 杨森制药公司 1,2,4-triazol [4,3-a] pyridine derivate and the purposes of the positive allosteric modulators as MGLUR2 acceptor thereof
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
US8865754B2 (en) 2011-03-03 2014-10-21 Proteotech Inc. Compounds for the treatment of neurodegenerative diseases
BR112013023984A2 (en) 2011-03-24 2016-09-13 Cellzome Ltd triazolyl piperazine and triazolyl piperidine derivatives substituted as gamma secretase modulators
US9120785B2 (en) 2011-05-10 2015-09-01 Merck Sharp & Dohme Corp. Pyridyl aminopyridines as Syk inhibitors
US9145391B2 (en) 2011-05-10 2015-09-29 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as Syk inhibitors
RU2013154412A (en) * 2011-05-10 2015-06-20 Мерк Шарп И Доум Корп. AMINOPYRIMIDINES AS SYC INHIBITORS
MX2014000626A (en) 2011-07-15 2014-04-30 Janssen Pharmaceuticals Inc Novel substituted indole derivatives as gamma secretase modulators.
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
EP2664619B1 (en) 2012-05-16 2017-07-12 Manros Therapeutics Purine derivatives as tools for screening anti-Alzheimer compounds
MX355164B (en) 2012-05-16 2018-04-06 Janssen Pharmaceuticals Inc Substituted 3, 4 - dihydro - 2h - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) alzheimer's disease.
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
EP2687528A1 (en) * 2012-07-17 2014-01-22 Ares Trading S.A. Fused triazole derivatives as gamma secretase modulators
US9717710B2 (en) 2012-10-05 2017-08-01 Vtv Therapeutics Llc Treatment of mild and moderate Alzheimer's disease
WO2014096212A1 (en) 2012-12-20 2014-06-26 Janssen Pharmaceutica Nv NOVEL TRICYCLIC 3,4-DIHYDRO-2H-PYRIDO[1,2-α]PYRAZINE-1,6-DIONE DERIVATIVES AS GAMMA SECRETASE MODULATORS
JP6283691B2 (en) 2013-01-17 2018-02-21 ヤンセン ファーマシューティカ エヌ．ベー． Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
EP2968296B1 (en) 2013-03-12 2020-09-02 The Regents of the University of California Gamma-secretase modulators
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
JO3368B1 (en) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
HUE062265T2 (en) 2013-06-27 2023-10-28 Pfizer Heteroaromatic compounds and their use as dopamine d1 ligands
US20150045353A1 (en) * 2013-08-09 2015-02-12 Neurogenetic Pharmaceuticals, Inc. Formulations containing gamma secretase modulators, methods for preparation and delivery thereof
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
CN106029072A (en) 2013-08-28 2016-10-12 麦迪韦逊技术股份有限公司 Heterocyclic compounds and methods of use
MX371343B (en) * 2013-09-04 2020-01-27 Ralexar Therapeutics Inc Liver x receptor (lxr) modulators.
JO3367B1 (en) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
WO2015109109A1 (en) 2014-01-15 2015-07-23 Forum Pharmaceuticals Inc. Fused morpholinopyrimidines and methods of use thereof
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
ES2860298T3 (en) 2014-01-21 2021-10-04 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators of metabotropic glutamatergic receptor subtype 2 and their use
EA033889B1 (en) 2014-01-21 2019-12-05 Янссен Фармацевтика Нв Combination comprising sv2a ligand and positive allosteric modulator of metabotropic glutamatergic receptor subtype 2
JO3512B1 (en) 2014-03-26 2020-07-05 Astex Therapeutics Ltd Quinoxaline derivatives useful as fgfr kinase modulators
AU2015238301B2 (en) 2014-03-26 2020-06-25 Astex Therapeutics Ltd Combinations
MX2016012368A (en) 2014-03-26 2017-02-23 Astex Therapeutics Ltd Combinations of an fgfr inhibitor and an igf1r inhibitor.
BR112017002053A2 (en) 2014-08-01 2018-01-30 Nuevolution A/S compound according to formula (i), pharmaceutical composition, and uses of a compound
SG10202006053UA (en) 2014-08-04 2020-07-29 Nuevolution As Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
WO2016070107A1 (en) * 2014-10-31 2016-05-06 The General Hospital Corporation Potent gamma-secretase modulators
US10221172B2 (en) 2015-01-13 2019-03-05 Vanderbilt University Benzothiazole and benzisothiazole-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
EP3053920B1 (en) * 2015-02-05 2020-04-08 AB Science Compounds with anti-tumoral activity
JOP20200201A1 (en) 2015-02-10 2017-06-16 Astex Therapeutics Ltd Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
AU2016224975B2 (en) * 2015-02-27 2020-10-22 The Regents Of The University Of California Small molecules that enable cartilage rejuvanation
EP3265457A1 (en) 2015-03-04 2018-01-10 Medivation Technologies LLC Sterol regulatory element-binding proteins (srebps) inhibitors
WO2016141159A1 (en) 2015-03-04 2016-09-09 Medivation Technologies, Inc. Srebp blockers for use in treating liver fibrosis, elevated cholesterol and insulin resistance
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
HUE057044T2 (en) * 2015-04-07 2022-04-28 Ela Pharma Ltd Compositions for treating and/or preventing cell or tissue necrosis specifically targeting cathepsin c and/or cela1 and/or cela3a and/or structurally related enzymes thereto
WO2016201168A1 (en) 2015-06-10 2016-12-15 Forum Pharmceuticals Inc. Oxadiazine compounds and methods of use thereof
WO2016202935A1 (en) 2015-06-19 2016-12-22 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
DK3353164T3 (en) 2015-09-23 2022-01-24 Janssen Pharmaceutica Nv BI-HETEROARYL SUBSTITUTED 1,4-BENZODIAZEPINES AND USES FOR CANCER TREATMENT
ES2811845T3 (en) 2015-09-23 2021-03-15 Janssen Pharmaceutica Nv Tricyclic heterocycles for treating cancer
EP3554502A4 (en) 2016-12-16 2021-01-06 Pipeline Therapeutics, Inc. Methods of treating cochlear synaptopathy
IL272838B2 (en) 2017-10-06 2023-09-01 Forma Therapeutics Inc Inhibiting ubiquitin specific peptidase 30
WO2019190823A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
CN108997328B (en) * 2018-09-06 2021-06-08 广东东阳光药业有限公司 Iminothiadiazine dioxide derivatives and their use
JP2022501431A (en) 2018-09-18 2022-01-06 ニカング セラピューティクス， インコーポレイテッド Condensed tricyclic ring derivative as Src homology-2 phosphatase inhibitor
AU2019356011A1 (en) 2018-10-05 2021-04-01 Forma Therapeutics, Inc. Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors
TWI767148B (en) 2018-10-10 2022-06-11 美商弗瑪治療公司 Inhibiting fatty acid synthase (fasn)
JP7464591B2 (en) 2018-10-10 2024-04-09 ブイティーブイ・セラピューティクス・エルエルシー Metabolite of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US11608329B2 (en) * 2019-12-20 2023-03-21 Ikena Oncology, Inc. Aryl hydrocarbon receptor (AHR) agonists and uses thereof
WO2021124277A1 (en) 2019-12-20 2021-06-24 Nuevolution A/S Compounds active towards nuclear receptors
TWI794742B (en) 2020-02-18 2023-03-01 美商基利科學股份有限公司 Antiviral compounds
IL296723A (en) 2020-03-26 2022-11-01 Seagen Inc Methods of treating multiple myeloma
AU2021249530A1 (en) 2020-03-31 2022-12-01 Nuevolution A/S Compounds active towards nuclear receptors
JP2023519603A (en) 2020-03-31 2023-05-11 ヌエヴォリューション・アクティーゼルスカブ Compounds active against nuclear receptors
EP4149941A1 (en) 2020-05-15 2023-03-22 Algen Biotechnologies, Inc. Certain chemical compositions and methods of use thereof
WO2022221514A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
DE202023102123U1 (en) 2023-04-21 2023-05-02 Mohammad Tauquir Alam Morpholinyl-phenylamino-thiazole derivatives as DNA gyrase inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594010A (en) * 1993-06-21 1997-01-14 Bayer Aktiengesellschaft Substituted monopyridylmethyl derivatives

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184A (en) * 1849-03-13 Door-lock
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4410645A (en) * 1981-06-15 1983-10-18 Ppg Industries, Inc. Aqueous sizing composition and sized glass fibers and method
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
JPS62142168A (en) 1985-10-16 1987-06-25 Mitsubishi Chem Ind Ltd Thiazole derivative and leukotriene antagonistic agent containing said derivative as active ingredient
DE3601196A1 (en) * 1986-01-17 1987-07-23 Merck Patent Gmbh 1,4-DIHYDROPYRIDINE
US4826990A (en) 1987-09-30 1989-05-02 American Home Products Corporation 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5028875A (en) * 1989-04-27 1991-07-02 Texas Tech University Linear rotary differential capacitance transducer
JPH0727609Y2 (en) * 1989-07-03 1995-06-21 アルプス電気株式会社 Variable resistor
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (en) 1990-04-17 1994-11-18 Eurand Int METHOD FOR THE TARGETED AND CONTROLLED DELIVERY OF DRUGS IN THE INTESTINE AND PARTICULARLY IN THE COLON
ATE260974T1 (en) 1990-06-15 2004-03-15 Scios Inc TRANSGENIC NON-HUMAN MAMMAL EXHIBITING THE AMYLOID-FORMING PATHOLOGY OF ALZHEIMER'S DISEASE
US5048736A (en) * 1990-06-26 1991-09-17 Anatra Enterprises, Inc. Coupon holder
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
JP2786336B2 (en) 1991-03-04 1998-08-13 富士写真フイルム株式会社 Immunoassay element and immunoassay method
US5672805A (en) 1991-07-18 1997-09-30 The Regents Of The University Of California Transgenic mice expressing the neurotoxic C-terminus of β-amyloid precursor protein
AU2765992A (en) 1991-10-03 1993-05-03 Indiana University Foundation Method for screening for alzheimer's disease
PT620849E (en) 1992-01-07 2003-11-28 Elan Pharm Inc TRANSGENIC ANIMAL MODELS FOR ALZHEIMER'S DISEASE
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US6024975A (en) 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5958883A (en) 1992-09-23 1999-09-28 Board Of Regents Of The University Of Washington Office Of Technology Animal models of human amyloidoses
WO1994018172A1 (en) * 1993-02-01 1994-08-18 Yoshitomi Pharmaceutical Industries, Ltd. Imidazolylbenzene compound and use thereof as medicine
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
EP0692972B2 (en) * 1993-04-02 2012-03-21 AntiCancer, Inc. Method for delivering beneficial compositions to hair follicles
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
ES2155099T3 (en) 1993-10-27 2001-05-01 Elan Pharm Inc TRANSGENIC ANIMALS THAT HOST APP ALELOS THAT PRESENT A SWEDISH MUTATION.
JPH07132033A (en) 1993-11-12 1995-05-23 Hoechst Japan Ltd Transgenic animal for alzheimer's disease model
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
CA2198451A1 (en) 1994-09-01 1996-03-07 Gurparkash Singh Transgenic animal expressing a familial form of human amyloid precursor protein
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6187992B1 (en) 1994-12-05 2001-02-13 Merck & Co., Inc. Transgenic mouse having a disrupted amyloid precursor protein gene
US5983134A (en) 1995-04-23 1999-11-09 Electromagnetic Bracing Systems Inc. Electrophoretic cuff apparatus drug delivery system
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US6167301A (en) 1995-08-29 2000-12-26 Flower; Ronald J. Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
WO1997036898A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
EP1007012A4 (en) 1996-10-01 2006-01-18 Cima Labs Inc Taste-masked microcapsule compositions and methods of manufacture
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US6187797B1 (en) 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
JP4395200B2 (en) 1997-10-28 2010-01-06 バンドー化学株式会社 Skin patch sheet and method for producing substrate sheet therefor
NZ506101A (en) * 1998-01-28 2003-06-30 Shionogi & Co Tricyclic immunosupressant, anti-allergic and IgE production suppressant compounds
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6037621A (en) * 1998-07-29 2000-03-14 Lucent Technologies Inc. On-chip capacitor structure
JP2002531504A (en) * 1998-12-07 2002-09-24 スミスクライン・ビーチャム・コーポレイション MYT1 kinase inhibitor
US6448272B1 (en) * 1998-12-07 2002-09-10 Smithkline Beecham Corporation Myt1 kinase inhibitors
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
US6080082A (en) * 1999-06-11 2000-06-27 Eaton Corporation Engine output torque control for powertrain with engageable positive clutches
JP2001114690A (en) * 1999-08-06 2001-04-24 Takeda Chem Ind Ltd p38MAP KINASE INHIBITOR
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
US20030176454A1 (en) * 2000-05-15 2003-09-18 Akira Yamada N-coating heterocyclic compounds
JP2002121597A (en) 2000-10-18 2002-04-26 Mitsui Chemicals Inc Bleaching agent composition
US6511229B2 (en) 2000-12-21 2003-01-28 Teradyne, Inc. Methods and apparatus for controlling access to an optical interface
US6642227B2 (en) * 2001-04-13 2003-11-04 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
CA2447884A1 (en) * 2001-05-25 2002-12-05 Schering Corporation Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
WO2003007955A2 (en) * 2001-07-20 2003-01-30 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
WO2003027101A1 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Substituted 3-pyridyl pyrroles and 3-pyridyl pyrazoles as c17,20 lyase inhibitors
JP2005509616A (en) * 2001-10-16 2005-04-14 センジェント・セラピューティクス・インク Organic sulfur inhibitors for tyrosine phosphatase
US20030158199A1 (en) 2002-01-25 2003-08-21 Kylix, B.V. Novel compounds for inhibition of Tie-2
JP2003313176A (en) * 2002-04-24 2003-11-06 Sankyo Co Ltd Aminoazole derivative
EP1519723A1 (en) * 2002-06-27 2005-04-06 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
GB2408071B (en) 2002-08-17 2005-10-19 Siemens Magnet Technology Ltd Pressure relief valve for a helium gas compressor
WO2004018997A2 (en) 2002-08-20 2004-03-04 Neurogenetics, Inc. Methods and compositions for modulating amyloid beta
CL2003002353A1 (en) 2002-11-15 2005-02-04 Vertex Pharma COMPOUNDS DERIVED FROM DIAMINOTRIAZOLS, INHIBITORS D ELA PROTEINA QUINASA; PHARMACEUTICAL COMPOSITION; PREPARATION PROCEDURE; AND ITS USE OF THE COMPOUND IN THE TREATMENT OF DISEASES OF ALLERGIC DISORDERS, PROLIFERATION, AUTOIMMUNES, CONDIC
BRPI0410348A (en) * 2003-05-14 2006-05-30 Torreypines Therapeutics Inc compounds and uses thereof in amyloid-beta modulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594010A (en) * 1993-06-21 1997-01-14 Bayer Aktiengesellschaft Substituted monopyridylmethyl derivatives

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9365548B2 (en) 2006-03-31 2016-06-14 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
US9434715B2 (en) 2013-03-06 2016-09-06 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine modulators of the histamine H4 receptor

Also Published As

Publication number Publication date
AU2004247013B2 (en) 2010-07-08
JP2011079852A (en) 2011-04-21
US8119680B2 (en) 2012-02-21
US20070260058A1 (en) 2007-11-08
IL171471A (en) 2013-02-28
WO2004110350A2 (en) 2004-12-23
EP1628666A2 (en) 2006-03-01
JP4847868B2 (en) 2011-12-28
US7799808B2 (en) 2010-09-21
CN102584813B (en) 2016-07-06
CN102584813A (en) 2012-07-18
US20100331551A1 (en) 2010-12-30
BRPI0410348A (en) 2006-05-30
CA2525547C (en) 2012-07-03
AU2004247013A1 (en) 2004-12-23
US20070249833A1 (en) 2007-10-25
US7781442B2 (en) 2010-08-24
US20100324032A1 (en) 2010-12-23
US7244739B2 (en) 2007-07-17
US8017629B2 (en) 2011-09-13
EP1628666B1 (en) 2015-09-23
JP5292381B2 (en) 2013-09-18
JP2007504282A (en) 2007-03-01
CA2525547A1 (en) 2004-12-23
MXPA05012281A (en) 2006-05-19
KR20060023529A (en) 2006-03-14
US20050070538A1 (en) 2005-03-31
EP1628666A4 (en) 2007-12-05

Similar Documents

Publication Publication Date Title
WO2004110350A3 (en) Compouds and uses thereof in modulating amyloid beta
WO2004113277A3 (en) Methods and compositions for treating amyloid-related diseases
EP1765388B8 (en) Combination therapy for preventing or treating alzheimer's disease, and kit therefor
EP1731113B8 (en) Medical treatment kit
AU2003297859A1 (en) Biomolecular coupling methods using 1,3-dipolar cycloaddition chemistry
IL173299A0 (en) Methods of treating or preventing autoimmune diseases with 2,4- pyrimidinediamine compounds
WO2004098494A3 (en) Compounds, compositions, and methods
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
WO2005046434A8 (en) Compositions and methods for diagnosing and treating mental disorders
WO2008054676A3 (en) Medical devices and methods of using the same
WO2005118551A3 (en) Thrombopoietin activity modulating compounds and methods
WO2005044093A3 (en) Delta-9- the treatment of multiple sclerosis
WO2007059116A3 (en) Geldanamycin derivatives and pharmaceutical compositions thereof
WO2005000208A3 (en) Combination therapy for the treatment of neoplasms
WO2006044155A3 (en) Ophthalmic compositions including lubricant, deturgescent agent, and glycosaminoglycan and methods of using the same
AU2003903242A0 (en) Process for the treatment of wood
EP1670894B8 (en) Compositions including different types of transfer factor, methods for making the compositions, and methods of treatment using the compositions
WO2004105696A3 (en) Combination therapy for the treatment of neoplasms
WO2005005382A3 (en) Compounds, compositions and methods
AU2003290142A1 (en) Multiroll calender
GB0325211D0 (en) Footwear liners and method for making the same
WO2005072241A3 (en) Inhibition of bright function as a treatment for excessive immunoglobulin production
WO2004078142A3 (en) Compositions and methods for preventing and treating endotoxin-related diseases and conditions
AU2003258176A1 (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
AP2005003369A0 (en) Knock-down drums.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 171471

Country of ref document: IL

Ref document number: 4753/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004247013

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004247013

Country of ref document: AU

Date of ref document: 20040514

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2525547

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2004247013

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005/09153

Country of ref document: ZA

Ref document number: 20048127844

Country of ref document: CN

Ref document number: 1020057021516

Country of ref document: KR

Ref document number: 2006533094

Country of ref document: JP

Ref document number: 200509153

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/012281

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 544014

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2004752297

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004752297

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057021516

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0410348

Country of ref document: BR